Search the Newsreel

Is AirSculpt (AIRS) Reaffirming Revenue Guidance to Highlight Discipline or Mask Profitability Pressures?

Ocular Therapeutix (OCUL) Is Up 9.2% After Wider Q2 Loss and New US$81.7M Shelf Registration

Almuneef Co. for Trading Industry Agriculture & Contraracting Revenue Breakdown – TADAWUL:9569

Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Cuts Target Price to $2

Maxim Group has reiterated its Buy rating for Moleculin Biotech (MBRX.US) but has reduced the target price for the stock to $2. This adjustment reflects a revised outlook on the company's valuation while maintaining a positive long-term perspective.

AirSculpt Technologies (NASDAQ:AIRS) Stock Rating Lowered by Wall Street Zen

Wall Street Zen has downgraded AirSculpt Technologies (NASDAQ:AIRS) from a "buy" to a "hold" rating, following the company's recent miss on quarterly earnings and revenue expectations. AirSculpt reported $0.01 EPS against an expected $0.02 and $42.9 million in revenue versus $44.14 million anticipated. Despite …

Moleculin Biotech Releases Q2 2026 Financial Results

Moleculin Biotech (MBRX) reported a net loss of $7.6 million for Q2 2026, with a significant improvement in loss per share, narrowing to $1.40 from $12.25 in Q2 2025. The company, focused on therapeutic candidates for tumors and viruses, generated no revenue but continued …

H.C. Wainwright reiterates Buy on 4D Molecular stock, $36 target By Investing.com

H.C. Wainwright has reiterated a Buy rating on 4D Molecular Therapeutics (NASDAQ:FDMT) with a $36.00 price target, citing positive two-year data from the Phase 2b PRISM trial for its 4D-150 gene therapy. The company has also completed enrollment for its pivotal Phase 3 4FRONT-2 …

Moleculin Biotech (NASDAQ: MBRX) seeks reverse split and plan changes at 2026 meeting

Moleculin Biotech (NASDAQ: MBRX) is holding its 2026 annual shareholder meeting on October 9, 2026, where key proposals include electing directors, ratifying the independent auditor, and approving an amendment to the 2024 Equity Incentive Plan to increase authorized shares. Shareholders will also vote on …

Pop Culture Group (CPOP): Alyeska discloses 9.99% stake via shares and warrants

Alyeska Investment Group, L.P., along with Alyeska Fund GP, LLC and Anand Parekh, has disclosed a 9.99% beneficial stake in Pop Culture Group Co., Ltd. (CPOP). This stake, reported via a SCHEDULE 13G filing, comprises 1,346,764 Class A Ordinary Shares, including shares held outright …

Agriculture & Natural Solutions (ANSC) to redeem shares and wind down SPAC

Four Oculis directors' restricted stock units vest in Aug. 13 notifications

Oculis (NASDAQ: OCS) announced that restricted stock units (RSUs) granted to directors Anthony Rosenberg, Christina Ackermann, Arshad Khanani, and Robert Warner vested on August 13, 2026. The company published notifications regarding these vesting and settlement transactions. While the announcement confirms the RSU vests for …

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Oculis Holding AG has published notifications regarding transactions by persons discharging managerial responsibilities. These notifications relate to the vesting and settlement of Restricted Stock Units (RSUs) previously granted to company directors. The listed individuals include Anthony Rosenberg, Christina Ackermann, Arshad Khanani, and Robert Warner, …

Cullinan Therapeutics, Inc. - Common Stock (CGEM) Stock Price, News, Quote & History

This article provides comprehensive information on Cullinan Therapeutics, Inc. (CGEM), including its current stock price, financial metrics, and a history of recent news and press releases. The company, a biopharmaceutical firm, focuses on developing cancer therapies and has announced several key clinical milestones and …

Avoiding Lag: Real-Time Signals in (SRL) Movement

Scully Royalty Ltd. (NYSE: SRL) is showing strong near and mid-term sentiment, with a potential for long-term extension. AI models have generated three trading strategies (position, momentum breakout, risk hedging) with an exceptional 73.5:1 risk-reward setup targeting a 27.9% gain versus 0.4% risk. The …

Fort Baker Capital discloses 4.2% ANSC stake in Schedule 13G/A filing (ANSC)

Fort Baker Capital Management LP, along with Steven Patrick Pigott and Fort Baker Capital, LLC, has reported a beneficial ownership of 1,379,630 Class A ordinary shares in Agriculture & Natural Solutions Acquisition Corp (ANSC). This stake represents 4.2% of the outstanding Class A shares, …

Oculis (NASDAQ:OCS) Price Target Cut to $20.00 by Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. has reduced its price target for Oculis (NASDAQ:OCS) to $20.00 from $23.00, while maintaining an "overweight" rating. Despite this reduction and similar cuts by other firms, Oculis still holds a consensus "Moderate Buy" rating with an average price target of …

Cullen/Frost Bankers (NYSE:CFR) Hits New 12-Month High - What's Next?

Cullen/Frost Bankers Inc stock hits all-time high at 170.34 USD

Cullen/Frost Bankers Inc. stock reached an all-time high of $170.34, demonstrating significant growth with a 36.66% increase over the past year. The company, which has a market cap of $10.54 billion and offers a 2.44% dividend yield with 33 years of consecutive dividend raises, …

OCUL|Ocular Therapeutix Inc|Price:9.890|Chg%:-0.210

This article provides detailed financial and analytical data for Ocular Therapeutix Inc (OCUL), including its live stock price, chart, news, and a comprehensive stock score. It covers key financial figures, performance over various periods, technical analysis, analyst ratings, and company profile. The data shows …

Form 8K FEDERAL AGRICULTURAL MORTGAGE CORPORATION For: 14 August By Investing.com

This article reports that FEDERAL AGRICULTURAL MORTGAGE CORPORATION has filed a Form 8K on August 14. The filing is brief and primarily serves as a notification of the SEC document. The article includes general market data and related news but offers no further details …

Stifel reiterates Buy rating on Oculis stock, $40 target

Stifel has reiterated a Buy rating and a $40 price target for Oculis Holding AG (NASDAQ:OCS), based on discussions about its lead asset, privosegtor. Despite a recent stock drop and an "overvalued" assessment by InvestingPro, analysts maintain a strong buy consensus. Oculis is shifting …

Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect?

Shares of Oculis Holding AG (OCS) have recently gained 1.7%, and Wall Street analysts project a potential rally of 187.83%, with a mean estimate of $36.9. Despite the inherent skepticism surrounding analyst price targets, a strong agreement among analysts on OCS's earnings potential and …

Moleculin Biotech GAAP EPS of -$1.40 misses by $0.53

* Moleculin Biotech press release [https://seekingalpha.com/pr/20619725-moleculin-biotech-reports-second-quarter-2026-financial-results-and-highlights-continued] (MBRX [https://seekingalpha.com/symbol/MBRX]): Q2 GAAP EPS of -$1.40 misses by $0.53. * As of June 30, 2026, the company had cash and cash equivalents of approximately $7.3 million. Management believes that its cash on hand and cash equivalents as …

Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial

Moleculin Biotech reported its second-quarter 2026 financial results, highlighting significant progress in its pivotal Phase 2/3 MIRACLE trial for Annamycin in relapsed or refractory AML. Positive interim data showed complete remission rates three times higher than the control group, with enrollment on track for …

Scully Royalty Installs Executive Chairman as Interim CEO and CFO

Allegro Culture Signals Return to Profit on Advertising Growth

Ocular Therapeutix (NASDAQ:OCUL) Raised to "Hold" at Zacks Research

Zacks Research upgraded Ocular Therapeutix (NASDAQ:OCUL) from a "strong sell" to a "hold" rating. Despite this change, the consensus among analysts remains a "Moderate Buy" with an average price target of $25.75, reflecting broad positive sentiment. The company recently reported better-than-expected quarterly results, with …

Scully Royalty Ltd. (NYSE: SRL) shifts chairman into interim CEO and CFO roles

Scully Royalty Ltd. has appointed its Chairman, Michael J. Smith, as interim Chief Executive Officer and Chief Financial Officer, replacing Samuel Morrow who will now serve as a non-executive director. Smith will oversee executive leadership while the company searches for permanent replacements. The company …

Hercules Capital closes $300 million notes offering at 5.35% interest By Investing.com

Hercules Capital (NYSE:HTGC) has successfully closed an underwritten public offering of $300 million in 5.350% notes due February 10, 2029. The specialty finance company plans to use the net proceeds to fund investments, repay existing secured debt, and for general corporate purposes. This move …

Allegro Culture Sets Board Meeting to Approve Interim Results

China Cultural Tourism and Agriculture Group Sets Board Meeting on Interim Results and Dividend

Scully Royalty Ltd (SRL) Earnings Forecast: Future EPS & Revenue Growth Estimates

Scully Royalty names interim CEO and CFO as chairman steps in during leadership search

Scully Royalty Ltd. has appointed Chairman Michael Smith as interim CEO and CFO, replacing Samuel Morrow, who will remain a non-executive director. Smith will oversee executive functions while the company searches for permanent leadership. The company has committed to maintaining disciplined financial oversight during …